Structural
Aortic Valve Disease Learning Series
TAVR Devices & Ancillary Tools
Episodes
The INFLOW TAVR System: Polymeric and Biological Designs with a Unique Self-Positioning Delivery System
13 min.
SIEGEL TAVR: Technology Update and EFS Results (Mirus Medical)
10 min.
Novel Balloon-Expandable Transcatheter Heart Valve for Aortic Stenosis: Insights from the First-In-Human Series (Abbott)
12 min.
Long-Term Outcomes After TAVR With a Self-Expanding Prosthesis
12 min.
Stroke and Cerebral Embolic Protection Devices in Contemporary TAVR Practice
12 min.
Presentation 3: Siegel TAVR
12 min.
Presentation 2: DurAVR
8 min.
Presentation 1: Encantor TAVR
8 min.
LIVE Case Presentation: New Self-Expanding TAVR (Navitor) - Leeds General Infirmary, Leeds, UK
37 min.
Latest Clinical Insights: Bridging Evidence and Practice
31 min.
Efficacy of CEP Devices to Reduce Stroke during TAVR: Insights From the TVT Registry
15 min.
Mitigating Stroke Risk in TAVR: Global Burden and the Role of Embolic Protection
13 min.
Updates from the Sentinel Clinical Trial Program: PROTECTED TAVR and BHF PROTECT-TAVI Meta-Analysis
13 min.
Untangling The Knot: Defining Appropriate Clinical Trial Endpoints and the Path Forward
11 min.
Technology and Clinical Update: Arch Deflector Devices
7 min.
Featured Research: A Prospective, Single-Arm, Multicenter Feasibility Trial to Evaluate the Safety and Performance of the F2 Filter and Delivery System Used for Embolic Protection During TAVR
13 min.
Technology and Clinical Update: Aortic Capture and Removal Filters
17 min.
Outcomes from the Optimize PRO Evolut FX System Addendum Study: 30-Day and 1-Year Results
12 min.
Advantages of Splitting Bicuspid Aortic Valve Leaflets Prior to TAVR: A New Paradigm for Leaflet Modification in BAV?
13 min.
BONAPART: A Novel Mechanical Leaflet Splitting Device
13 min.
The Evolution of Leaflet Modification Technologies: Emerging Techniques (e.g. UNICORN, BATMAN, etc), Technologies and Future Applications
8 min.
Anatomic Considerations for Device Selection: Are Device v Device Trials Meaningful?
12 min.
SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results
12 min.
One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial
22 min.
ACURATE IDE Trial: Editorial Commentary
8 min.
TCT 1359: Management Strategies of Paravalvular Leak in the Post-TAVR Patient: To Plug or to Balloon?
9 min.
TCT 1190: Hostile Aorta: Valve, Grafts, Stents and Plug for Intervention
5 min.
Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial
18 min.
Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation: The ACCESS-TAVI Randomized Trial
14 min.
TCT 1212: Case of a First Dedicated Splitting Device in Failed TAVR Valve
5 min.
The NAVITOR Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities
6 min.
The EVOLUT Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities
17 min.
The SAPIEN Balloon-Expandable TAVR Program: Technology Focus and Clinical Trial Priorities
16 min.
Valve Fracturing During Surgical Valve-in-Valve Procedures
19 min.
TAVR Therapy for Chronic AR: Focus on Dedicated TAVR Devices
9 min.
Where Do We Go Next?
20 min.
What Data and Valve Design Means for Valve Selection in Women
14 min.
FX+: The Next Step in Addressing Lifetime Management
8 min.
Not All Valves Are Designed Alike
7 min.
Mid-term outcomes of balloon expandable TAVR: do gradients and gender matter?
11 min.
The Design of the Navitor Vision Valve
7 min.
Unsuccessful or Complicated Leaflet Modification in TAVR
19 min.
Leaflet Modification for TAV-in-TAV
5 min.
TELLTALE for TAV-in-SAV or TAV-in-Native
5 min.
BASILICA or ShortCut for TAV-in-SAVR or TAV-in-TAV
5 min.
Is Leaflet Modification Sufficient to Prevent Coronary Obstruction - When to Consider Snorkel Stenting
16 min.
The 2024 'Toolbox' for Leaflet Modification in TAVR
6 min.
Can TAV-in-TAV Simulations be Useful in Procedural Planning?
11 min.
The Future is Now! TAVR is a Favorable Alternative in AS Patients Under 65 Years Old
17 min.
TAVR in Young Patients - Current Treatment Patterns in the US
16 min.
LIVE Case: New TAVR -The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
25 min.
LIVE Case: New TAVR - The Heart Center Leipzig, University Hospital, Leipzig, Germany
36 min.
Understanding the Fundamentals of the ACURATE Platform
15 min.
Restoration of flow from CMR: Laminar Flow Impact on Outcomes
21 min.
Hemodynamic Performance and Restoration of Laminar Flow
7 min.
Clinical Results with the DurAVR THV System
18 min.
A New Class of TAVR, A New Design Target
16 min.
Trilogy TAVR in the Real World: An EU Implanter’s Experience with the Trilogy System
17 min.
The Trilogy TAVR System and an Update on the ALIGN-AR Study
19 min.
Leaflet Modification Using the Shortcut Before Transcatheter Aortic Valve Replacement in Patients at Risk for Coronary Obstruction: Intra-Procedural Imaging Assessments of an International Case Experience
16 min.
Case Presentation 2: TAVR in Bicuspid AS with SEV
8 min.
Case Presentation 1: TAVR in Bicuspid AS with BEV
4 min.
Device Selection and Sizing in TAVR for Bicupsid AS
16 min.
Vascular Access Complications (Ascending Aorta to CFA) – Percutaneous Repair Strategies
13 min.
Live Case: TAVR- AR – The Heart Center, Rigshospitalet, Copenhagen University, Hospital, Copenhagen, Denmark
36 min.
Live Case: AR TAVR - Cardiovascular Institute of the South (CVIS), Houma, LA
23 min.
Lessons From Off Label TAVR Use in Pure AR – Tips & Tricks
13 min.
Current Status of Dedicated Valve Platforms for Pure Aortic Regurgitation and Update on Trial Data
17 min.
Impact of Cerebral Embolic Protection Devices on Disabling Stroke After Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry
16 min.